ArticleCurrent pharmaceutical design2022

Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.

Irine Pauly et al.PubMed ↗Publisher ↗

No numbers read from the abstract.